Reference number
2756-H

SPECIALTY QUANTITY LIMIT PROGRAM

Vizimpro (dacomitinib)

I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Vizimpro 15 mg tablets	30 per 30 days	Standard dosing: 45 mg per day Recommended dose reductions for adverse reactions: - First dose reduction: 30 mg per day - Second dose reduction: 15 mg per day
Vizimpro 30 mg tablets		
Vizimpro 45 mg tablets		

III. REFERENCES

1. Vizimpro [package insert]. New York, NY: Pfizer, Inc.; September 2018.